Tolcapone in the management of Parkinson's disease

被引：0
|
作者：
Pilipovich, A. A. [1 ]
Golubev, V. L. [1 ]
机构：
[1] IM Sechenov Med Acad, Moscow, Russia
来源：
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA | 2007年 / 107卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：71 / 78
页数：8
相关论文
共 50 条
  • [21] Gait analysis in advanced Parkinson's disease - effect of levodopa and tolcapone
    Shan, DE
    Lee, SJ
    Chao, LY
    Yeh, SI
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2001, 28 (01) : 70 - 75
  • [22] Heart rate variability in Parkinson's disease patients treated with tolcapone
    Meco, G
    Vanacore, N
    Locuratolo, N
    Bonifati, V
    Vella, C
    Giovani, A
    Tubani, L
    Baratta, L
    Mastrocola, C
    [J]. PARKINSONISM & RELATED DISORDERS, 2000, 6 (04) : 223 - 227
  • [23] Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone
    Welsh, MD
    Dorflinger, E
    Chernik, D
    Waters, C
    [J]. MOVEMENT DISORDERS, 2000, 15 (03) : 497 - 502
  • [24] Tolcapone-Related Liver DysfunctionImplications for Use in Parkinson’s Disease Therapy
    Nuno Borges
    [J]. Drug Safety, 2003, 26 : 743 - 747
  • [25] Micro- and Nano-Systems Developed for Tolcapone in Parkinson's Disease
    Casanova, Yaquelyn
    Negro, Sofia
    Slowing, Karla
    Garcia-Garcia, Luis
    Fernandez-Carballido, Ana
    Rahmani, Mahdieh
    Barcia, Emilia
    [J]. PHARMACEUTICS, 2022, 14 (05)
  • [26] Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
    Lees, A. J.
    Ratziu, V.
    Tolosa, E.
    Oertel, W. H.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (09): : 944 - 948
  • [27] The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease
    Ondo, WG
    Hunter, C
    Vuong, KD
    Jankovic, J
    [J]. PARKINSONISM & RELATED DISORDERS, 2000, 6 (04) : 237 - 240
  • [28] Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
    Waters, CH
    Kurth, M
    Bailey, P
    Shulman, LM
    LeWitt, P
    Dorflinger, E
    Deptula, D
    Pedder, S
    [J]. NEUROLOGY, 1997, 49 (03) : 665 - 671
  • [29] Tolcapone (TASMAR®) in the treatment of advanced Parkinson's disease:: Results of a postmarketing surveillance study
    Ebersbach, G.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S244 - S244
  • [30] Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease
    Factor, SA
    Molho, ES
    Feustel, PJ
    Brown, DL
    Evans, SM
    [J]. CLINICAL NEUROPHARMACOLOGY, 2001, 24 (05) : 295 - 299
12345